SOURCE: MD Biosciences

August 12, 2008 13:00 ET

MD Biosciences to Showcase Pre-Clinical Capabilities at the 12th World Congress on Pain

ZURICH, SWITZERLAND--(Marketwire - August 12, 2008) - MD Biosciences, a global biotechnology company focused in inflammations & neurology research, will showcase its pre-clinical capabilities at the 12th World Congress on Pain (IASP) in Glasgow, Scotland, August 17th - 22nd, 2008. Capabilities included in the showcase are efficacy disease models within Nociceptive, Neuropathic, Post-operative and Inflammatory Pain.

Nociceptive Pain is part of a rapid warning relay instructing the motor neurons of the central nervous system to minimize detected physical harm. Disease models include the Tail Flick Model -- used to measure the response to noxious stimuli, the Visceral Pain Model -- used to measure the effectiveness of analgesic agents, the Caspaicin model -- used to evaluate response mediated by the VR1 pathway, and Post-operative pain models for screening the pathophysiology of hyperalgesia.

Neuropathic Pain is produced by damage to the neurons in the peripheral and central nervous systems. Disease models include the Chronic Constriction Injury (CCI, Bennett & Xie) model -- involves inflammation around the nerve, the Taxol induced Neuropathic Pain model -- causing peripheral nerve ending injury, the Spinal Nerve Ligation (Chung) Model -- nerve ligation between L5 & L6, and the STZ Diabetic Neuropathy model -- direct destruction of the nerve associated with high levels of glucose.

Inflammatory Pain is associated with tissue damage and the resulting inflammatory response. Disease models include the Carrageenan Induced Inflammatory Pain, Adjuvant (CFA) induced Inflammatory Pain and Arthritic Pain.

Additional models are offered as requested along with end-point readouts such as biomarker analysis, histology, and gene expression analysis. MD Biosciences will also be showcasing its capabilities at additional events this fall including the Inflammations Research Association (IRA) in September and the American College of Rheumatology (ACR) in October.

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

Contact Information